NRSNW
NeuroSense Therapeutics Ltd. WarrantKey Statistics
About NeuroSense Therapeutics Ltd. Warrant
NeuroSense Therapeutics Ltd. is a pioneering biotechnology company dedicated to advancing innovative therapies for neurodegenerative diseases, particularly amyotrophic lateral sclerosis (ALS). The company’s lead candidate strategically targets the underlying mechanisms of disease progression, aiming to provide transformative treatment solutions for patients. Utilizing a multi-modal approach that integrates diverse therapeutic strategies, NeuroSense distinguishes itself in the competitive neurotherapeutics sector. Committed to robust clinical development and scientific rigor, NeuroSense is poised to make impactful contributions to the biopharmaceutical field and enhance treatment options for those suffering from debilitating neurological disorders.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-11.07M |
| Operating Margin | 0.00% |
| Return on Equity | -2175.00% |
| Return on Assets | -247.30% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $-0.05 |
| Price-to-Book | — |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | — |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | 0 |
| Float | $26.03M |
| % Insiders | 0.00% |
| % Institutions | 0.00% |